The purpose of this study is to implement a support interdisciplinary program(oncologists, pharmacists, physicians, nurses, leagues against cancer) of medication adherence to oral oncology treatments. The aim is to ensure continuity of care between professionals,effectiveness of treatment and patient safety.
Primary Outcome Measures:
Secondary Outcome Measures:
- Program implementation [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Evaluating the implementation of the program in pharmacies
- Oncologists, nurses, pharmacists and patients satisfaction [ Time Frame: 1 year ] [ Designated as safety issue: No ]
By questionnaire and interviews
- Effect of Adverse Drug Reaction (ADR) on medication adherence [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
By MEMS data and motivational interviewing informations
- Change in Adverse Drug Reaction (ADR) [ Time Frame: 3 months, 6 months, 9 months, 12 months ] [ Designated as safety issue: Yes ]
To evaluate the frequency and severity of ADR and the pharmacist's contribution to their management. Data from motivational interviewing.
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Primary Completion Date:
||December 2011 (Final data collection date for primary outcome measure)
Adults (18 years old or more) with one of the following oral oncology treatments: letrozole, exémestane, imatinib, sunitinib, nilotinib, evérolimus, déférasirox
80 patients will be included in swiss-romande hospitals and private oncologists and followed by thirty study pharmacies. Each refusal and drop-out will be documented. Follow-up duration is 48 weeks, with a motivational interviewing at least every three months. Patient adherence will be assessed electronically by MEMS (Medication Event Monitoring System).